Lv11
50 积分 2024-11-24 加入
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma
20天前
已完结
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
27天前
已完结
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
28天前
已完结
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)
29天前
已完结
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non–Small Cell Lung Cancer (ZEAL-1L)
29天前
已关闭
Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers
1个月前
已完结
20 years of the Stupp protocol: confronting stagnation in glioblastoma therapy
1个月前
已完结
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
1个月前
已完结
Considerations in Kp,uu,brain-based Strategy for Selecting CNS-targeted Drug Candidates with Sufficient Target Coverage and Substantial Pharmacodynamic Effect
1个月前
已完结
Two decades of PARP inhibitor synthetic lethality in cancer
1个月前
已完结
皖公网安备34019202002308
